Persano et al. 64reported that, besides being an effective prodifferentiation treatment for GBM-derived stem cells, BMP2 also sensitized GICs to temozolomide (TMZ) treatment by decreasing hypoxia-inducible factor 1 alpha (HIF1α) stability and consequently down-regulating O-6-methylguanine-DNA methyltransferase (MGMT), an HIF1α target, thereby promoting TMZ’s alkylating action. The gene discussed is MGMT; the disease is glioblastoma.